Equity Research

July 18, 2023 BSE Sensex: 66590

ICICI Securities Limited is the author and distributor of this report

| Company | update and |
|-------------|------------|
| target pric | e revision |

Consumer Staples & Discretionary

Target price Rs1,400

Target price revision Rs1,400 from Rs1,300

Shareholding pattern

| | Sep '22 | Dec '22 | Mar '23 |
|---------------|------------|------------|------------|
| Promoters | 73.0 | 73.0 | 73.0 |
| Institutional | | | |
| investors | 25.9 | 25.6 | 25.6 |
| MFs and other | 22.5 | 22.3 | 22.2 |
| Insurance co | 0.0 | 0.0 | 0.0 |
| FIIs | 3.4 | 3.3 | 3.4 |
| Others | 1.1 | 1.4 | 1.4 |
| Source: BSF | | | |

ESG disclosure score

| Year | 2020 | 2021 | Chg | | |
|--|------|------|-----|--|--|
| ESG score | NA | NA | NA | | |
| Environment | NA | NA | NA | | |
| Social | NA | NA | NA | | |
| Governance | NA | NA | NA | | |
| Note - Score ranges from 0 - 100 with a higher score | | | | | |

indicating higher ESG disclosure Source: Bloomberg, I-sec research

Research Analysts:

Manoj Menon

manoj.menon@icicisecurities.com +91 22 6807 7209 Varun Singh

varun.singh@icicisecurities.com +91 22 6807 7649

Karan Bhuwania karan.bhuwania@icicisecurities.com

+91 22 6807 7351 **Akshay Krishnan**

akshay.krishnan@icicisecurities.com +91 22 6807 7632

INDIA Sheela Foam



BUY Maintained

Rs1.187

Acquisitions are accretive

Acquisition of Kurlon is positive for the stakeholders of Sheela Foam: (1) SHEELA's market share in South and East India has room for improvement (vs North and West India where it enjoys ~40% market share). Given, KURLON is no. 2 player in South India with ~40% revenue share, this deal is likely to augment SHEELA's overall market share in mattress segment from current 20-25% to 35-40%. (2) Business economics of Kurlon are attractive (at 7.2% pre-covid net margin vs 7.5% for SHEELA – refer Chart 3) and shall be largely EPS accretive to SHEELA (assuming normalized margins). (3) Renewed focus shall help KURLON to claw-back market share loss (to Duroflex) in South India led by efficient execution, distribution expansion and higher support towards brand promotion. (4) Robust distribution network (SHEELA has higher presence in EBOs while KURLON has higher presence in MBOs) and production efficiencies (better servicing of customers) & cost savings (reduced cost to serve and manufacturing cost) are the synergies expected by the management. (5) Acquisition of Furlenco (digital first brand in fast growing branded furniture category) is likely to drive footfalls to EBOs through introducing complementary product portfolio (branded furniture) in their EBOs, in our view. We await further clarity on rationale and synergies of these acquisitions.

Sheela Foam has acquired 94.66% and 35% of Kurlon Enterprises and House of Kieraya (Furlenco) at Rs20.4bn (implied normalised FY23 P/S multiple of 1.5x vs 4x P/S of Sheela) and Rs3bn (implied FY23 P/S multiple of 5.6x), respectively.

Our positive stance on Sheela Foam is based on the long-term opportunities which also embellish the narrative – (a) benefit from China+ strategy of buyers in the US, Europe, (b) opportunity in furniture cushioning and manufacturing, (c) sustained acceleration in India business growth (competitive edge through 5,000+ EBO network), (d) consumers realizing importance of good quality mattress and (e) focus on growing e-commerce channel. BUY.

Sheela to gain strength in South and East: Currently, Sheela enjoys significant market share in North and West India (~40% vs 25% all-India) due to first-mover advantage (founded in UP in 1971; operated factories in Sahidabad and Noida for 25 years before expanding into Mumbai and Hyderabad in 1996). However, Kurlon's revenue share from South stands at 40%+; the company started its business journey from Karnataka (>5 out of 12 factory located in Bangalore) and hence enjoys higher market share in South (now no. 2 player). The acquisition will help Sheela to gain significant distribution/brand strength in South and East India. Also, revenue contribution from B2C segment for Sheela shall improve.

| Market Cap | Rs116bn/US\$1.4bn | Year to March | FY22 | FY23 | FY24E | FY25E |
|------------------------|-------------------|---------------------|--------|--------|--------|--------|
| Reuters/Bloomberg | SHVF.BO / SFL IN | Net Revenue (Rs mn) | 28,656 | 28,733 | 31,820 | 35,917 |
| Shares Outstanding (n | nn) 97.6 | Net Profit (Rs mn) | 2,187 | 2,031 | 2,880 | 3,748 |
| 52-week Range (Rs) | 1630/638 | Dil. EPS (Rs) | 22.4 | 20.8 | 29.5 | 38.4 |
| Free Float (%) | 27.0 | % Chg YoY | (8.9) | (7.2) | 41.8 | 30.2 |
| FII (%) | 3.4 | P/E (x) | 53.0 | 57.0 | 40.2 | 30.9 |
| Daily Volume (US\$'000 | 0) 799 | CEPS (Rs) | 30.7 | 30.0 | 40.4 | 50.5 |
| Absolute Return 3m (% | 6) 14.6 | EV/EBITDA (x) | 36.9 | 39.1 | 28.1 | 23.1 |
| Absolute Return 12m (| %) (10.3) | Dividend Yield (%) | - | - | - | - |
| Sensex Return 3m (%) |) 11.9 | RoCE (%) | 13.5 | 10.0 | 13.1 | 14.4 |
| Sensex Return 12m (% | 6) 25.4 | RoE (%) | 16.9 | 13.5 | 16.4 | 18.0 |

Please refer to important disclosures at the end of this report


- Opportunity for KEL to claw-back market share loss: Over last 3 years (FY20-22) Duroflex (80%+ revenue from South India; Karnataka, Kerala, Tamil Nadu, Telangana and Andhra Pradesh) has gained significant market share (2x as per our estimate) from KEL. We believe, this was driven by superior product portfolio (PU based), aggressive incentivisation of channels and discount/promotions. Hence, despite higher revenue growth (2.3x over last 3-year vs 0.8x for KEL), net and EBITDA margin for Duroflex has been significantly lower at 4% (vs 7% for Kurlon). We believe, the acquisition shall significantly improve KEL's strength in product offering and hence enable the company to claw-back market share loss from Duroflex.
- Healthy margins and ROE: KEL's business economics (net margin, EBITDA margin and ROE) stand at healthy levels; better than Duroflex (refer Chart 3, 4 and 5). KEL's business economics are very similar to Sheela Foam with EBITDA margin, EBITDA margin and ROE of ~12% / ~12%, 7.5% / 7.2% and 21% / 19%, respectively.
- Valuation and risks: We increase our earnings estimates by 5%/4% for FY24E/FY25E due to better gross margin expectations driven by correction in input cost; modelling revenue / EBITDA / PAT CAGR of 12% / 30% / 36% over FY23-25E. Maintain BUY with a DCF-based revised target price of Rs1,400 (Rs1,300 earlier). Key downside risks are (1) adverse movement in prices of key inputs and (2) increase in competition from global players/Indian e-commerce.

Table 1: Revenue (Rs mn)

| FY | SHEELA | KURLON | DUROFLEX |
|------|--------|--------|----------|
| FY18 | 19,653 | 11,206 | 3,237 |
| FY19 | 21,415 | 10,639 | 3,897 |
| FY20 | 21,736 | 9,956 | 4,315 |
| FY21 | 24,354 | 7,673 | 5,728 |
| FY22 | 28,656 | 8,088 | 9,003 |
| | | | |

Source: Company data, I-Sec research

Chart 1: Duroflex gained market share



Source: Company data, I-Sec research

Chart 2: EBITDA margin (pre-covid – FY18-20)






Chart 4: Healthy ROE (pre-covid – FY18-20)




Source: Company data, I-Sec research

Chart 3: Net Margin % (pre-covid – FY18-20)



Source: Company data, I-Sec research

Chart 5: TDI price change




Source: Company data, I-Sec research

Chart 6: Kurlon took birth in Karnataka; started with coir (60+years), ventured into PU (34+ years) and spring (16+ years)

| Started as Karnataka Coir Products Pvt Ltd with one factory in Arsikere - a small town in Karnataka. 1962 | Kurl-On bags its first railway order. 1969 | Initiates in-house production of polyurethane foam. Pioneers the quilted mattress concept and becomes the first mattress brand to advertise on print and TV. 1988 | Becomes an ISO 9001 certified company. 2000 | Starts the manufacture of spring mattresses at the Bangalore factory. Also introduces products like sofas and indigenous furnitures. 20006 | Establishes 9 strategically- located manufacturing facilities across Karnataka, Orissa, Madhya Pradesh, Uttarakhand and Gujarat. 2013 | First brand to launch concept mattress called Wedding series. 2019 | Sixty years of helping India sleep healthy. 2022 |
|---|---|--|--|---|---|--|---|
| 1965 Rubberized Coir mattress Jaunches in India | 1972 Wins contract to manufacture car seats for Mahindra & Mahindra, Hindustan Motors. | 1995 Introduces the campaign - 'Stand on, Sit on, Sleep on, Kuri-on.' | 2002 Enters the retail industry with Kurlon Nest: the company's first retail venture across India. | 2010 Starts the first franchise outlet - Kurl-on Mattress Express. | 2016 Upgrades products with cutting-edge Kurlopedic Technology. | 2021 Brand launches revolutionary Mattress in a bag concept. | |

Source: Company data, I-Sec research

Chart 7: Sheela took birth in U.P.; started with PU Foam (51+ years), ventured into coir (23+ years)



Source: Company data, I-Sec research

Chart 8: Brands of Kurlon








Source: Company data, I-Sec research


Chart 9: Manufacturing presence

Kurlon: Manufacturing presence



Source: Company data, I-Sec research


Chart 10: Revenue growth (consolidated)



Source: Company data, I-Sec research


Chart 11: Gross margin (consolidated)

Sheela: Manufacturing presence




Source: Company data, I-Sec research

Chart 12: EBITDA margin (consolidated)




Source: Company data, I-Sec research

Chart 14: Other expenses as a % of sales




Source: Company data, I-Sec research

Chart 13: Staff cost as a % of sales




Source: Company data, I-Sec research

Chart 15: TDI price change



Source: Company data, I-Sec research



Financial summary

Table 2: Profit & Loss statement

(Rs mn, year ending March 31)

| | FY22 | FY23 | FY24E | FY25E |
|-----------------------------|--------|--------|--------|--------|
| Net Revenues | 28,656 | 28,733 | 31,820 | 35,917 |
| Operating Expenses | 25,506 | 25,760 | 27,679 | 30,883 |
| EBITDA | 3,149 | 2,973 | 4,142 | 5,034 |
| % margins | 11.0 | 10.3 | 13.0 | 14.0 |
| Depreciation & Amortisation | 808 | 896 | 1,062 | 1,174 |
| Gross Interest | 170 | 211 | 221 | 221 |
| Other Income | 792 | 865 | 990 | 1,370 |
| Recurring PBT | 2,964 | 2,731 | 3,848 | 5,009 |
| Less: Taxes | 776 | 700 | 969 | 1,261 |
| Less: Minority Interest | - | - | - | - |
| Net Income (Reported) | 2,187 | 2,031 | 2,880 | 3,748 |
| Extraordinaries (Net) | - | - | - | - |
| Recurring Net Income | 2,187 | 2,031 | 2,880 | 3,748 |

Source: Company data, I-Sec research

Table 3: Balance sheet

(Rs mn, year ending March 31)

| <u> </u> | FY22 | FY23 | FY24E | FY25E |
|---|--------|--------|--------|--------|
| Assets | | | | |
| Total Current Assets | 7,865 | 14,333 | 17,618 | 21,896 |
| of which cash & cash eqv. | 1,305 | 7,545 | 11,314 | 14,784 |
| Total Current Liabilities & Provisions | 4,364 | 4,966 | 5,501 | 6,212 |
| Net Current Assets | 3,501 | 9,367 | 12,117 | 15,685 |
| Investments | 6,300 | 1,784 | 1,976 | 2,230 |
| Net Fixed Assets | 8,269 | 8,116 | 8,054 | 7,980 |
| Capital Work-in-Progress | 1,199 | 2,875 | 2,875 | 2,875 |
| Goodwill | 2,520 | 2,740 | 2,740 | 2,740 |
| Total Assets | 19,269 | 22,142 | 25,022 | 28,770 |
| Liabilities | | | | |
| Borrowings | 4,665 | 5,711 | 5,711 | 5,711 |
| Deferred Tax Liability | 602 | 345 | 345 | 345 |
| Minority Interest | - | - | - | - |
| Equity Share Capital | 244 | 488 | 488 | 488 |
| Face Value per share (Rs) | 3 | 5 | 5 | 5 |
| Reserves & Surplus* | 13,758 | 15,599 | 18,478 | 22,226 |
| Net Worth | 14,002 | 16,087 | 18,966 | 22,714 |
| Total Liabilities | 19,269 | 22,142 | 25,022 | 28,770 |

Source: Company data, I-Sec research

Table 4: Quarterly trends

(Rs mn, year ending March 31)

| | Jun 22 | Sep 22 | Dec 22 | Mar 23 |
|-----------------------|--------|--------|--------|--------|
| Net Revenues | 7,291 | 7,222 | 7,609 | 7,290 |
| % growth (YoY) | 32.3 | (8.1) | (13.7) | (1.0) |
| EBITDA | 659 | 783 | 757 | 774 |
| Margin (%) | 9.0 | 10.8 | 10.0 | 10.6 |
| Other income | 184 | 225 | 282 | 174 |
| Extraordinaries (Net) | - | - | - | - |
| Adjusted Net profit | 425 | 536 | 612 | 458 |

Source: Company data, I-Sec research

Table 5: Cashflow statement

.

| (Rs mn, year ending March | 31) | | | |
|--|---------|---------|---------|---------|
| | FY22 | FY23 | FY24E | FY25E |
| Operating Cash flow | 2,560 | 2,668 | 2,981 | 3,519 |
| Working Capital Changes | (589) | (548) | 1,018 | (98) |
| Capital Commitments | (1,635) | (2,116) | (1,000) | (1,100) |
| Free Cash Flow | 337 | 4 | 3,000 | 2,321 |
| Cash flow from Investing Activities | (3,064) | (2,684) | (231) | 49 |
| Issue of Share Capital | - | (5) | - | - |
| Inc (Dec) in Borrowings | 1,207 | 876 | - | - |
| Dividend paid | (37) | (28) | - | - |
| Change in Deferred Tax Liability | (165) | (3) | 3,769 | 3,470 |
| Chg. in Cash & Bank balance | 411 | 425 | 4,194 | 7,664 |

Source: Company data, I-Sec research

Table 6: Key ratios

(Year ending March 31)

| Per Share Data (Rs)EPS22.420.829.538.4Cash EPS30.730.040.450.5Dividend per share (DPS)Book Value per share (BV)143.5164.9194.4232.8Growth (%)Net Sales17.70.310.712.9EBITDA(13.1)(5.6)39.321.5PAT(8.9)(7.2)41.830.2DPSValuation Ratios (x)P/E53.057.040.230.9P/CEPS38.739.629.423.5P/BV8.37.26.15.1EV / EBITDA36.939.128.123.1EV / Sales4.14.03.73.2Operating RatiosRaw Material / Sales (%)65.562.259.0SG&A / Sales (%)14.617.818.318.1Other Income / PBT (%)26.731.725.727.4Effective Tax Rate (%)26.225.625.225.2Working Capital (days)33.731.917.917.9Inventory Turnover (days)40.142.134.034.0Receivables (days)36.433.033.033.0Net D/E Ratio (x)0.1(0.2)(0.3)(0.4)Profitability Ratio (%)Net D/E Ratio (x)0.1(0.2)(0.3)(0.4) <th></th> <th>FY22</th> <th>FY23</th> <th>FY24E</th> <th>FY25E</th> | | FY22 | FY23 | FY24E | FY25E |
|--|---------------------------|-------|------------|-------|--------|
| EPS 22.4 20.8 29.5 38.4 Cash EPS 30.7 30.0 40.4 50.5 Dividend per share (DPS) - - - - Book Value per share (BV) 143.5 164.9 194.4 232.8 Growth (%) (13.1) (5.6) 39.3 21.5 PAT (8.9) (7.2) 41.8 30.2 DPS - - - - Valuation Ratios (x) - - - - P/E 53.0 57.0 40.2 30.9 P/CEPS 38.7 39.6 29.4 23.5 P/BV 8.3 7.2 6.1 5.1 EV / EBITDA 36.9 39.1 28.1 23.1 EV / Sales 4.1 4.0 3.7 3.2 Operating Ratios - - - - Raw Material / Sales (%) 65.5 62.2 59.0 58.5 Employee cost / Sales (%) 8.9 9.7 9.6 9.4 SG&A / Sales (%) <td< td=""><td>Per Share Data (Rs)</td><td></td><td></td><td></td><td></td></td<> | Per Share Data (Rs) | | | | |
| Dividend per share (DPS) Book Value per share (BV) 143.5 164.9 194.4 232.8 Growth (%) Net Sales 17.7 0.3 10.7 12.9 EBITDA (13.1) (5.6) 39.3 21.5 PAT (8.9) (7.2) 41.8 30.2 DPS - - - - Valuation Ratios (x) P/E 53.0 57.0 40.2 30.9 P/E 53.0 57.0 40.2 30.9 S&& <t< td=""><td></td><td>22.4</td><td>20.8</td><td>29.5</td><td>38.4</td></t<> | | 22.4 | 20.8 | 29.5 | 38.4 |
| Book Value per share (BV) 143.5 164.9 194.4 232.8 Growth (%) Net Sales 17.7 0.3 10.7 12.9 EBITDA (13.1) (5.6) 39.3 21.5 PAT (8.9) (7.2) 41.8 30.2 DPS - - - - Valuation Ratios (x) P/E 53.0 57.0 40.2 30.9 P/CEPS 38.7 39.6 29.4 23.5 P/BV 8.3 7.2 6.1 5.1 EV / EBITDA 36.9 39.1 28.1 23.1 EV / Sales 4.1 4.0 3.7 3.2 Operating Ratios Raw Material / Sales (%) 65.5 62.2 59.0 58.5 Employee cost / Sales (%) 14.6 17.8 18.3 18.1 Other Income / PBT (%) 26.7 31.7 25.7 27.4 Effective Tax Rate (%) 26.2 25.6 25.2 25.2 Working Capital (days) 33.7 </td <td>Cash EPS</td> <td>30.7</td> <td>30.0</td> <td>40.4</td> <td>50.5</td> | Cash EPS | 30.7 | 30.0 | 40.4 | 50.5 |
| Growth (%) | Dividend per share (DPS) | - | - | - | - |
| Net Sales 17.7 0.3 10.7 12.9 EBITDA (13.1) (5.6) 39.3 21.5 PAT (8.9) (7.2) 41.8 30.2 DPS - - - - - Valuation Ratios (x) P/E 53.0 57.0 40.2 30.9 P/CEPS 38.7 39.6 29.4 23.5 P/BV 8.3 7.2 6.1 5.1 EV / EBITDA 36.9 39.1 28.1 23.1 EV / Sales 4.1 4.0 3.7 3.2 Operating Ratios - - - - Raw Material / Sales (%) 65.5 62.2 59.0 58.5 Employee cost / Sales (%) 14.6 17.8 18.3 18.1 Other Income / PBT (%) 26.7 31.7 25.7 27.4 Effective Tax Rate (%) 26.2 25.6 25.2 25.2 Working Capital (days) 33.7 31.9 | Book Value per share (BV) | 143.5 | 164.9 | 194.4 | 232.8 |
| Net Sales 17.7 0.3 10.7 12.9 EBITDA (13.1) (5.6) 39.3 21.5 PAT (8.9) (7.2) 41.8 30.2 DPS - - - - - Valuation Ratios (x) P/E 53.0 57.0 40.2 30.9 P/CEPS 38.7 39.6 29.4 23.5 P/BV 8.3 7.2 6.1 5.1 EV / EBITDA 36.9 39.1 28.1 23.1 EV / Sales 4.1 4.0 3.7 3.2 Operating Ratios - - - - Raw Material / Sales (%) 65.5 62.2 59.0 58.5 Employee cost / Sales (%) 14.6 17.8 18.3 18.1 Other Income / PBT (%) 26.7 31.7 25.7 27.4 Effective Tax Rate (%) 26.2 25.6 25.2 25.2 Working Capital (days) 33.7 31.9 | Growth (%) | | | | |
| EBITDA (13.1) (5.6) 39.3 21.5 PAT (8.9) (7.2) 41.8 30.2 DPS - - - - Valuation Ratios (x) - - - - P/E 53.0 57.0 40.2 30.9 P/CEPS 38.7 39.6 29.4 23.5 P/BV 8.3 7.2 6.1 5.1 EV / EBITDA 36.9 39.1 28.1 23.1 EV / Sales 4.1 4.0 3.7 3.2 Operating Ratios - - - - Raw Material / Sales (%) 65.5 62.2 59.0 58.5 Employee cost / Sales (%) 8.9 9.7 9.6 9.4 SG&A / Sales (%) 14.6 17.8 18.3 18.1 Other Income / PBT (%) 26.7 31.7 25.7 27.4 Effective Tax Rate (%) 26.2 25.6 25.2 25.2 Working Capital (days) 33.7 31.9 17.9 17.9 Inven | | 177 | 03 | 10.7 | 12.0 |
| PAT (8.9) (7.2) 41.8 30.2 DPS - - - - - Valuation Ratios (x) P/E 53.0 57.0 40.2 30.9 P/CEPS 38.7 39.6 29.4 23.5 P/BV 8.3 7.2 6.1 5.1 EV / EBITDA 36.9 39.1 28.1 23.1 EV / Sales 4.1 4.0 3.7 3.2 Operating Ratios Raw Material / Sales (%) 65.5 62.2 59.0 58.5 Employee cost / Sales (%) 8.9 9.7 9.6 9.4 SG&A / Sales (%) 14.6 17.8 18.3 18.1 Other Income / PBT (%) 26.7 31.7 25.7 27.4 Effective Tax Rate (%) 26.2 25.6 25.2 25.2 Working Capital (days) 33.7 31.9 17.9 17.9 Inventory Turnover (days) 40.1 42.1 34.0 34.0 Receivables (days) 36.4 33.0 33.0 33.0 Profitability | | | | - | - |
| DPS - - - - - Valuation Ratios (x) P/E 53.0 57.0 40.2 30.9 P/CEPS 38.7 39.6 29.4 23.5 P/BV 8.3 7.2 6.1 5.1 EV / EBITDA 36.9 39.1 28.1 23.1 EV / Sales 4.1 4.0 3.7 3.2 Operating Ratios Raw Material / Sales (%) 65.5 62.2 59.0 58.5 Employee cost / Sales (%) 8.9 9.7 9.6 9.4 SG&A / Sales (%) 14.6 17.8 18.3 18.1 Other Income / PBT (%) 26.7 31.7 25.7 27.4 Effective Tax Rate (%) 26.2 25.6 25.2 25.2 Working Capital (days) 33.7 31.9 17.9 17.9 Inventory Turnover (days) 40.1 42.1 34.0 34.0 Receivables (days) 36.4 33.0 33.0 33.0 Net D/E Ratio (x) 0.1 (0.2) (0.3) (0.4) <td></td> <td></td> <td></td> <td></td> <td></td> | | | | | |
| P/E 53.0 57.0 40.2 30.9 P/CEPS 38.7 39.6 29.4 23.5 P/BV 8.3 7.2 6.1 5.1 EV / EBITDA 36.9 39.1 28.1 23.1 EV / Sales 4.1 4.0 3.7 3.2 Operating Ratios Raw Material / Sales (%) 65.5 62.2 59.0 58.5 Employee cost / Sales (%) 8.9 9.7 9.6 9.4 SG&A / Sales (%) 14.6 17.8 18.3 18.1 Other Income / PBT (%) 26.7 31.7 25.7 27.4 Effective Tax Rate (%) 26.2 25.6 25.2 25.2 Working Capital (days) 33.7 31.9 17.9 17.9 Inventory Turnover (days) 40.1 42.1 34.0 34.0 Receivables (days) 36.4 33.0 33.0 33.0 Net D/E Ratio (x) 0.1 (0.2) (0.3) (0.4) RoACE 13.5 10.0 13.1 14.4 RoAE <td></td> <td>(0.3)</td> <td>(1.2) -</td> <td>-</td> <td>- 50.2</td> | | (0.3) | (1.2) - | - | - 50.2 |
| P/E 53.0 57.0 40.2 30.9 P/CEPS 38.7 39.6 29.4 23.5 P/BV 8.3 7.2 6.1 5.1 EV / EBITDA 36.9 39.1 28.1 23.1 EV / Sales 4.1 4.0 3.7 3.2 Operating Ratios Raw Material / Sales (%) 65.5 62.2 59.0 58.5 Employee cost / Sales (%) 8.9 9.7 9.6 9.4 SG&A / Sales (%) 14.6 17.8 18.3 18.1 Other Income / PBT (%) 26.7 31.7 25.7 27.4 Effective Tax Rate (%) 26.2 25.6 25.2 25.2 Working Capital (days) 33.7 31.9 17.9 17.9 Inventory Turnover (days) 40.1 42.1 34.0 34.0 Receivables (days) 36.4 33.0 33.0 33.0 Net D/E Ratio (x) 0.1 (0.2) (0.3) (0.4) RoACE 13.5 10.0 13.1 14.4 RoAE <td></td> <td></td> <td></td> <td></td> <td></td> | | | | | |
| P/CEPS 38.7 39.6 29.4 23.5 P/BV 8.3 7.2 6.1 5.1 EV / EBITDA 36.9 39.1 28.1 23.1 EV / Sales 4.1 4.0 3.7 3.2 Operating Ratios Raw Material / Sales (%) 65.5 62.2 59.0 58.5 Employee cost / Sales (%) 8.9 9.7 9.6 9.4 SG&A / Sales (%) 14.6 17.8 18.3 18.1 Other Income / PBT (%) 26.7 31.7 25.7 27.4 Effective Tax Rate (%) 26.2 25.6 25.2 25.2 Working Capital (days) 33.7 31.9 17.9 17.9 Inventory Turnover (days) 40.1 42.1 34.0 34.0 Receivables (days) 36.4 33.0 33.0 30.0 Payables (days) 36.4 33.0 33.0 33.0 Net D/E Ratio (x) 0.1 (0.2) (0.3) (0.4) Profitability Ratio (%) 7.6 7.1 9.0 10.4 | | | | | |
| P/BV 8.3 7.2 6.1 5.1 EV / EBITDA 36.9 39.1 28.1 23.1 EV / Sales 4.1 4.0 3.7 3.2 Operating Ratios Raw Material / Sales (%) 65.5 62.2 59.0 58.5 Employee cost / Sales (%) 8.9 9.7 9.6 9.4 SG&A / Sales (%) 14.6 17.8 18.3 18.1 Other Income / PBT (%) 26.7 31.7 25.7 27.4 Effective Tax Rate (%) 26.2 25.6 25.2 25.2 Working Capital (days) 33.7 31.9 17.9 17.9 Inventory Turnover (days) 40.1 42.1 34.0 34.0 Receivables (days) 36.4 33.0 33.0 33.0 Net D/E Ratio (x) 0.1 (0.2) (0.3) (0.4) Profitability Ratio (%) 5 7.6 7.1 9.0 10.4 RoACE 13.5 10.0 13.1 14.4 RoAE 16.9 13.5 16.4 18.0 | | | | - | |
| EV / EBITDA 36.9 39.1 28.1 23.1 EV / Sales 4.1 4.0 3.7 3.2 Operating Ratios Raw Material / Sales (%) 65.5 62.2 59.0 58.5 Employee cost / Sales (%) 8.9 9.7 9.6 9.4 SG&A / Sales (%) 14.6 17.8 18.3 18.1 Other Income / PBT (%) 26.7 31.7 25.7 27.4 Effective Tax Rate (%) 26.2 25.6 25.2 25.2 Working Capital (days) 33.7 31.9 17.9 17.9 Inventory Turnover (days) 40.1 42.1 34.0 34.0 Receivables (days) 36.4 33.0 33.0 30.0 Payables (days) 36.4 33.0 33.0 33.0 Net Income Margins 7.6 7.1 9.0 10.4 RoACE 13.5 10.0 13.1 14.4 RoAE 16.9 13.5 16.4 18.0 Dividend Payout - - - - <td></td> <td></td> <td></td> <td></td> <td></td> | | | | | |
| EV / Sales 4.1 4.0 3.7 3.2 Operating Ratios Raw Material / Sales (%) 65.5 62.2 59.0 58.5 Employee cost / Sales (%) 14.6 17.8 18.3 18.1 Other Income / PBT (%) 26.7 31.7 25.7 27.4 Effective Tax Rate (%) 26.2 25.6 25.2 25.2 Working Capital (days) 33.7 31.9 17.9 17.9 Inventory Turnover (days) 40.1 42.1 34.0 34.0 Receivables (days) 36.4 33.0 33.0 30.0 Payables (days) 36.4 33.0 33.0 33.0 Net D/E Ratio (x) 0.1 (0.2) (0.3) (0.4) Profitability Ratio (%) 7.6 7.1 9.0 10.4 RoACE 13.5 10.0 13.1 14.4 RoAE 16.9 13.5 16.4 18.0 Dividend Payout - - - - | | | | - | - |
| Operating RatiosRaw Material / Sales (%) 65.5 62.2 59.0 58.5 Employee cost / Sales (%) 8.9 9.7 9.6 9.4 SG&A / Sales (%) 14.6 17.8 18.3 18.1 Other Income / PBT (%) 26.7 31.7 25.7 27.4 Effective Tax Rate (%) 26.2 25.6 25.2 25.2 Working Capital (days) 33.7 31.9 17.9 17.9 Inventory Turnover (days) 40.1 42.1 34.0 34.0 Receivables (days) 34.3 35.8 30.0 30.0 Payables (days) 36.4 33.0 33.0 33.0 Net D/E Ratio (x) 0.1 (0.2) (0.3) (0.4) Profitability Ratio (%)Net Income Margins 7.6 7.1 9.0 10.4 RoAE 16.9 13.5 16.4 18.0 Dividend PayoutDividend Yield | | | | - | - |
| Raw Material / Sales (%) 65.5 62.2 59.0 58.5 Employee cost / Sales (%) 8.9 9.7 9.6 9.4 SG&A / Sales (%) 14.6 17.8 18.3 18.1 Other Income / PBT (%) 26.7 31.7 25.7 27.4 Effective Tax Rate (%) 26.2 25.6 25.2 25.2 Working Capital (days) 33.7 31.9 17.9 17.9 Inventory Turnover (days) 40.1 42.1 34.0 34.0 Receivables (days) 36.4 33.0 33.0 30.0 Payables (days) 36.4 33.0 33.0 33.0 Net D/E Ratio (x) 0.1 (0.2) (0.3) (0.4) Profitability Ratio (%) Net Income Margins 7.6 7.1 9.0 10.4 RoACE 13.5 10.0 13.1 14.4 RoACE 16.9 13.5 16.4 18.0 Dividend Payout - - - - | EV / Sales | 4.1 | 4.0 | 3.7 | 3.2 |
| Employee cost / Sales (%) 8.9 9.7 9.6 9.4 SG&A / Sales (%) 14.6 17.8 18.3 18.1 Other Income / PBT (%) 26.7 31.7 25.7 27.4 Effective Tax Rate (%) 26.2 25.6 25.2 25.2 Working Capital (days) 33.7 31.9 17.9 17.9 Inventory Turnover (days) 40.1 42.1 34.0 34.0 Receivables (days) 36.4 33.0 33.0 30.0 Payables (days) 36.4 33.0 33.0 33.0 Net D/E Ratio (x) 0.1 (0.2) (0.3) (0.4) Profitability Ratio (%) Net Income Margins 7.6 7.1 9.0 10.4 RoACE 13.5 10.0 13.1 14.4 RoAE 16.9 13.5 16.4 18.0 Dividend Payout - - - - | Operating Ratios | | | | |
| SG&A / Sales (%) 14.6 17.8 18.3 18.1 Other Income / PBT (%) 26.7 31.7 25.7 27.4 Effective Tax Rate (%) 26.2 25.6 25.2 25.2 Working Capital (days) 33.7 31.9 17.9 17.9 Inventory Turnover (days) 40.1 42.1 34.0 34.0 Receivables (days) 36.4 33.0 33.0 30.0 Payables (days) 36.4 33.0 33.0 33.0 Net D/E Ratio (x) 0.1 (0.2) (0.3) (0.4) Profitability Ratio (%) Net Income Margins 7.6 7.1 9.0 10.4 RoACE 13.5 10.0 13.1 14.4 RoAE 16.9 13.5 16.4 18.0 Dividend Payout - - - - | Raw Material / Sales (%) | 65.5 | 62.2 | 59.0 | 58.5 |
| Other Income / PBT (%) 26.7 31.7 25.7 27.4 Effective Tax Rate (%) 26.2 25.6 25.2 25.2 Working Capital (days) 33.7 31.9 17.9 17.9 Inventory Turnover (days) 40.1 42.1 34.0 34.0 Receivables (days) 36.4 33.0 33.0 30.0 Payables (days) 36.4 33.0 33.0 33.0 Net D/E Ratio (x) 0.1 (0.2) (0.3) (0.4) Profitability Ratio (%) Net Income Margins 7.6 7.1 9.0 10.4 RoACE 13.5 10.0 13.1 14.4 RoAE 16.9 13.5 16.4 18.0 Dividend Payout - - - - | Employee cost / Sales (%) | 8.9 | 9.7 | 9.6 | 9.4 |
| Effective Tax Rate (%) 26.2 25.6 25.2 25.2 Working Capital (days) 33.7 31.9 17.9 17.9 Inventory Turnover (days) 40.1 42.1 34.0 34.0 Receivables (days) 34.3 35.8 30.0 30.0 Payables (days) 36.4 33.0 33.0 33.0 Net D/E Ratio (x) 0.1 (0.2) (0.3) (0.4) Profitability Ratio (%) Net Income Margins 7.6 7.1 9.0 10.4 RoACE 13.5 10.0 13.1 14.4 RoAE 16.9 13.5 16.4 18.0 Dividend Payout - - - - | SG&A / Sales (%) | 14.6 | 17.8 | 18.3 | 18.1 |
| Working Capital (days) 33.7 31.9 17.9 17.9 Inventory Turnover (days) 40.1 42.1 34.0 34.0 Receivables (days) 34.3 35.8 30.0 30.0 Payables (days) 36.4 33.0 33.0 33.0 Net D/E Ratio (x) 0.1 (0.2) (0.3) (0.4) Profitability Ratio (%) Net Income Margins 7.6 7.1 9.0 10.4 RoACE 13.5 10.0 13.1 14.4 RoAE 16.9 13.5 16.4 18.0 Dividend Payout - - - - | Other Income / PBT (%) | 26.7 | 31.7 | 25.7 | 27.4 |
| Inventory Turnover (days) 40.1 42.1 34.0 34.0 Receivables (days) 34.3 35.8 30.0 30.0 Payables (days) 36.4 33.0 33.0 33.0 Net D/E Ratio (x) 0.1 (0.2) (0.3) (0.4) Profitability Ratio (%) X <th< td=""><td>Effective Tax Rate (%)</td><td>26.2</td><td>25.6</td><td>25.2</td><td>25.2</td></th<> | Effective Tax Rate (%) | 26.2 | 25.6 | 25.2 | 25.2 |
| Receivables (days) 34.3 35.8 30.0 30.0 Payables (days) 36.4 33.0 33.0 33.0 Net D/E Ratio (x) 0.1 (0.2) (0.3) (0.4) Profitability Ratio (%) | Working Capital (days) | 33.7 | 31.9 | 17.9 | 17.9 |
| Payables (days) 36.4 33.0 33.0 33.0 Net D/E Ratio (x) 0.1 (0.2) (0.3) (0.4) Profitability Ratio (%) | | 40.1 | | | |
| Net D/E Ratio (x) 0.1 (0.2) (0.3) (0.4) Profitability Ratio (%) | | | | | |
| Profitability Ratio (%) Net Income Margins 7.6 7.1 9.0 10.4 RoACE 13.5 10.0 13.1 14.4 RoAE 16.9 13.5 16.4 18.0 Dividend Payout - - - - Dividend Yield - - - - | | | | | |
| Net Income Margins 7.6 7.1 9.0 10.4 RoACE 13.5 10.0 13.1 14.4 RoAE 16.9 13.5 16.4 18.0 Dividend Payout - - - - Dividend Yield - - - - | Net D/E Ratio (x) | 0.1 | (0.2) | (0.3) | (0.4) |
| Net Income Margins 7.6 7.1 9.0 10.4 RoACE 13.5 10.0 13.1 14.4 RoAE 16.9 13.5 16.4 18.0 Dividend Payout - - - - Dividend Yield - - - - | Profitability Ratio (%) | | | | |
| RoACE 13.5 10.0 13.1 14.4 RoAE 16.9 13.5 16.4 18.0 Dividend Payout - - - - Dividend Yield - - - - | | 7.6 | 7.1 | 9.0 | 10.4 |
| RoAE 16.9 13.5 16.4 18.0 Dividend Payout - - - - - Dividend Yield - - - - - - | | - | | | |
| Dividend Payout Dividend Yield | | | | - | |
| Dividend Yield | | - | - | - | - |
| EBITDA Margins 11.0 10.3 13.0 14.0 | | - | - | - | - |
| | EBITDA Margins | 11.0 | 10.3 | 13.0 | 14.0 |

Source: Company data, I-Sec research

This report may be distributed in Singapore by ICICI Securities, Inc. (Singapore branch). Any recipients of this report in Singapore should contact ICICI Securities, Inc. (Singapore branch) in respect of any matters arising from, or in connection with, this report. The contact details of ICICI Securities, Inc. (Singapore branch) are as follows: Address: 10 Collyer Quay, #40-92 Ocean Financial Tower, Singapore - 049315, Tel: +65 6232 2451 and email: navneet_babbar@icicisecuritiesinc.com, Rishi_agrawal@icicisecuritiesinc.com.

"In case of eligible investors based in Japan, charges for brokerage services on execution of transactions do not in substance constitute charge for research reports and no charges are levied for providing research reports to such investors."

New I-Sec investment ratings (all ratings based on absolute return; All ratings and target price refers to 12-month performance horizon, unless mentioned otherwise) BUY: >15% return; ADD: 5% to 15% return; HOLD: Negative 5% to Positive 5% return; REDUCE: Negative 5% to Negative 15% return; SELL: < negative 15% return;

ANALYST CERTIFICATION

I/We, Manoj Menon, MBA, CMA; Varun Singh, MBA, Karan Bhuwania, MBA; Akshay Krishnan, MBA; authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of the ICICI Securities Inc. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager, Research Analyst and Alternative Investment Fund. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ00183631 for stock broker. ICICI Securities AIF Trust's SEBI Registration number is IN/AIF3/23-24/1292 ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Institutional Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Retail Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/ beneficial ownership of one percent or more or other material conflict of interest in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

This report has not been prepared by ICICI Securities, Inc. However, ICICI Securities, Inc. has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk free return to the investors.

Name of the Compliance officer (Research Analyst): Mr. Atul Agrawal, Contact number: 022-40701000, **E-mail Address** : <u>complianceofficer@icicisecurities.com</u> For any queries or grievances: <u>Mr. Prabodh Avadhoot</u> Email address: <u>headservicequality@icicidirect.com</u> Contact Number: 18601231122